We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+16.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$119M
AUM Growth
+$18.2M
Cap. Flow
+$7.39M
Cap. Flow %
6.19%
Top 10 Hldgs %
33.76%
Holding
75
New
17
Increased
23
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$3.55M
2
ALKS icon
Alkermes
ALKS
+$2.93M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$2.05M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.98M
5
NKTR icon
Nektar Therapeutics
NKTR
+$1.35M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.88M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.03M
3
PCYC
PHARMACYCLICS INC
PCYC
+$2.34M
4
UTHR icon
United Therapeutics
UTHR
+$2.11M
5
AMGN icon
Amgen
AMGN
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 76.66%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
26
DELISTED
Hologic
HOLX
$1.65M 1.38%
50,000
-3,000
-6% -$92.1K
ARRY
27
DELISTED
Array Biopharma Inc
ARRY
$1.47M 1.24%
200,000
– –
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$1.39M 1.16%
+15,000
New +$968K
VCEL icon
29
Vericel Corp
VCEL
$2.38B
$1.34M 1.12%
362,157
+78,887
+28% +$269K
TSRO
30
DELISTED
TESARO, Inc.
TSRO
$1.15M 0.96%
+20,000
New +$942K
STML
31
DELISTED
Stemline Therapeutics, Inc.
STML
$1.08M 0.91%
75,000
+4,600
+7% +$70.4K
XNPT
32
DELISTED
XENOPORT, INC.
XNPT
$926K 0.78%
130,000
-22,000
-14% -$171K
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$912K 0.76%
60,000
-10,000
-14% -$130K
EPZM
34
DELISTED
Epizyme, Inc
EPZM
$908K 0.76%
48,339
+20,000
+71% +$413K
UTHR icon
35
United Therapeutics
UTHR
$26.1B
$899K 0.75%
5,213
-13,841
-73% -$2.11M
ASMB icon
36
Assembly Biosciences
ASMB
$498M
$861K 0.72%
+5,417
New +$733K
OCRX
37
DELISTED
Ocera Therapeutics, Inc.
OCRX
$860K 0.72%
182,673
+60,000
+49% +$346K
MACK
38
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$855K 0.72%
9,152
– –
TENX icon
39
Tenax Therapeutics
TENX
$393M
$812K 0.68%
8
– –
EIGR
40
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$803K 0.67%
94
– –
AMGN icon
41
Amgen
AMGN
$209B
$789K 0.66%
4,938
-12,108
-71% -$1.91M
AVDL
42
DELISTED
Avadel Pharmaceuticals
AVDL
$751K 0.63%
41,788
– –
RARE icon
43
Ultragenyx Pharmaceutical
RARE
$2.46B
$745K 0.62%
+12,000
New +$667K
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$733K 0.61%
+25,000
New +$586K
BLUE
45
DELISTED
bluebird bio
BLUE
$725K 0.61%
+463
New +$611K
CMRX
46
DELISTED
Chimerix, Inc.
CMRX
$722K 0.61%
19,152
– –
XNCR icon
47
Xencor
XNCR
$1.45B
$685K 0.57%
44,698
– –
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$658K 0.55%
66,704
+16,704
+33% +$209K
RLYP
49
DELISTED
RELYPSA INC COM
RLYP
$649K 0.54%
+18,000
New +$649K
AERI
50
DELISTED
Aerie Pharmaceuticals
AERI
$627K 0.53%
+20,000
New +$580K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2015 Portfolio in Review

As of Q1 2015, Opus Point Partners Management held 75 positions worth $119M, up 18% from $101M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Opus Point Partners Management deployed $7.39M of net new capital in Q1 2015, opening 17 new positions and adding to 23 existing holdings. Its largest new stake was Pacira BioSciences: 34,949 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $3.03M trimmed.

  • Opus Point Partners Management's largest Q1 2015 buy was Pacira BioSciences: 34,949 shares worth $3.1M.
  • Opus Point Partners Management added most to Alkermes in Q1 2015, an estimated $2.93M increase.
  • Opus Point Partners Management's biggest Q1 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $3.03M.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q1 2015, selling an estimated $3.88M.
  • Opus Point Partners Management's ten largest holdings make up 34% of its $119M portfolio in Q1 2015.
  • Opus Point Partners Management opened 17 new positions and closed 10 in Q1 2015.
  • Opus Point Partners Management's portfolio value rose 18% quarter-over-quarter to $119M.

Based on Opus Point Partners Management's 13F filing for Q1 2015, filed 18 May 2015.